Available Assays
| Method Description | Department |
|---|---|
| Acetazolamide | LCMS |
| Acetylsalicylic acid (ASA), Salicylic acid (SAL) | LCMS |
| CBD + 7OH + 7COOH metabs | LCMS |
| CBD + 7OH + 7COOH + 6a-OH metabs (higher range) | LCMS |
| Dabigatran | LCMS |
| Dextromethorphan, Dextrorphan and 3-Methoxymorphinan | LCMS |
| Diclofenac | LCMS |
| Duloxetine | LCMS |
| E & Z-Endoxifen | LCMS |
| Entecavir | LCMS |
| Estradiol and Estrone (E1, E2) | LCMS |
| Glutathione (total), exploratory | LCMS |
| Hydroxychloroquine, DHCQ, DCQ and BDCQ | LCMS |
| Ketamine, Norketamine | LCMS |
| Ketamine, Norketamine [chiral] | LCMS |
| Lidocaine | LCMS |
| LPA 18:2 | LCMS |
| Mannitol | LCMS |
| Midazolam, Α-HYDROXYMIDAZOLAM | LCMS |
| Milrinone | LCMS |
| Monepantel and Monepantel Sulfone (exploratory) | LCMS |
| Moxifloxacin | LCMS |
| N-Acetylcysteine (total) | LCMS |
| Nicotine | LCMS |
| Nintedanib | LCMS |
| Oxycodone and Noroxycodone | LCMS |
| Oxycodone, Noroxycodone, Oxymorphone | LCMS |
| Oxymorphone, 6-hydroxy beta oxymorphone | LCMS |
| Paroxetine | LCMS |
| Phenylalanine | LCMS |
| Pravastatin | LCMS |
| Progesterone (P4) | LCMS |
| Psilocybin, Psilocin | LCMS |
| Quinidine | LCMS |
| Sildenafil | LCMS |
| Sildenafil and Desmethyl Sildenafil | LCMS |
| Tamoxifen and metabolites | LCMS |
| Tenofovir | LCMS |
| THC, CBD, CBN and two metabolites of THC | LCMS |
| Vancomycin | LCMS |
| DETERMINATION OF TOCILIZUMAB IN HUMAN SERUM USING THE GYROS IMMUNOASSAY PLATFORM | Immunoassay |
| DETERMINATION OF OMALIZUMAB IN HUMAN SERUM USING THE GYROS IMMUNOASSAY PLATFORM | Immunoassay |
| DETERMINATION OF USTEKINUMAB IN HUMAN SERUM USING THE GYROS IMMUNOASSAY PLATFORM | Immunoassay |
| PBMC isolation | Cellular Molecular |






